| Compound | LL-37 (Cathelicidin) |
|---|---|
| Category | Endogenous antimicrobial peptide |
| Class | Healing and Anti-Inflammatory Peptides |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers LL-37 (Cathelicidin), a endogenous antimicrobial peptide, graded "Preclinical" in this catalog's evidence system. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
The human cathelicidin antimicrobial peptide, studied for its roles in host defense, wound infection control, and inflammatory skin conditions. It is an endogenous immune molecule rather than a designed therapeutic.
Mechanism of Action
LL-37 disrupts microbial membranes and additionally binds to nucleic acids, modulating innate immune recognition. In psoriasis and rosacea, excessive LL-37 activity is implicated in disease, illustrating that more antimicrobial peptide is not always better.
Research and Evidence
Research spans in vitro antimicrobial work, wound-healing models, and studies of LL-37 dysregulation in inflammatory dermatoses. Direct therapeutic use in humans remains investigational.
Safety and Side Effects
As an endogenous immune mediator with pleiotropic effects, systemic administration carries real uncertainty; no approved LL-37 drug product exists.
Frequently Asked Questions
What is the evidence tier of LL-37 (Cathelicidin)?
LL-37 (Cathelicidin) is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is LL-37 (Cathelicidin) an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for LL-37 (Cathelicidin)?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for cathelicidin LL-37 studies. [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.